期刊文献+

RPSFT法在临床试验转组研究中的应用

Correcting for Non-compliance in Randomized Trials Using Rank Preserving Structural Failure Time Models
下载PDF
导出
摘要 目的介绍等级结构保留失效时间模型(rank preserving structural failure time models,RPSFT)在临床试验转组研究中的应用。方法以一项存在转组情况的阿帕替尼片的随机双盲、平行对照、多中心Ⅲ期临床研究为例,应用RFSFT法对转组数据进行校正,评估校正前后两组中位生存时间及组间风险比估计值变化情况。结果经过RPSFT法校正后,对照组的中位生存时间校正前高于校正后、组间风险比校正前也高于校正后,校正后两种治疗的长期效果差异更接近真实情况。结论 RPSFT法是英国国家健康与临床评价研究所(NICE)认可的方法,在转组临床试验研究中具有较大应用价值。 Objective To introduce rank preserving structural failure time models in the application of randomized trials with crossover. Methods Based on an randomized,duble blind,parallel group,multi- center,phase III Apatinib clinical trials with crossover,RPSFT models are developed,then we accessed the changes of the median survival time of control group and hazard ratio between groups. Results Both the median survival time of control group and hazard ratio between groups are higher than before corrected,which makes the difference of efficacy more closer to true effect. Conclusion NICE appraisal acknowledge RPSFT as being more methodologically robust,which is of high value in the application of randomized trials with crossover.
出处 《中国卫生统计》 CSCD 北大核心 2013年第6期812-814,共3页 Chinese Journal of Health Statistics
基金 国家自然科学基金(81273184)
关键词 转组 等级结构保留失效模型 加速失效时间模型 COX比例风险模型 Crossover Rank preserving structural failure time models Accelerated failure time model Cox proportional hazard model
  • 相关文献

参考文献12

  • 1Pfizer Limited,Single Technology Appraisal of Sunitinib for the treat-ment of gastrointestinal stromal tumours,October 2008,available fromhttp://www. nice. org. uk/nicemedia/live/12040/43440/43440. pdf,accessed 29 October,2010.
  • 2National Institute for Health & Clinical Excellence. Sunitinib for thetreatment of gastrointestinal stroma tumours. NICE technology appraisalguidance 179. September 2009.
  • 3Robins J,Tsiatis A. Correcting for non-compliance in randomised trialsusing rank preserving structure failure time models. Communications inStatistics- Theory and Methods, 1991,20:2609-2631.
  • 4White IR,Walker S,Babiker A. strbee:Randomization-based efficacy esti-mator. The Stata Journal 2002,2(Number 2) : 140-150. Abailable at :www.statajoumal. com/ris. php. articlenum = st0012&abs = l&type = ris.
  • 5White IR : Uses and limitations of randomization-based efficacy estima-tors. Statistical Methods in Medical Research,2005,14(4) :327-347.
  • 6Robins J,Tsiatis A. Correcting for non-compliance in randomised trialsusing rank preserving structure failure time models. Communications inStatistics- Theory and Methods ,1991,20: 2609-2631.
  • 7Mark S, Robins J. A method for the analysis of randomised trials withcompliance information : an application to the multiple risk factor inter-vention 16. trial. Controlled Clinical Trials, 1993,14 :79-97.
  • 8White IR,Babiker AG, Walker S,et al. Randomization-based methodsfor correcting for treatment changes : examples from the Concorde trial.Statistics in Medicine,1999,18:2617-2634.
  • 9National Institute for Health & Clinical Excellence. Sunitinib for thetreatment of gastrointestinal stroma tumours. NICE technology appraisalguidance 179. September,2009.
  • 10GSK. Pazopanib (Votrient.) for the first-line treatment of patients withadvanced renal cell carcinoma (RCC) ADDENDUM to GSK ’ S SUB-MISSION TO NICE 20 JULY 2010. http://www. nice. org. uk/nice-media/live/12032/52299/52299. pdf.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部